Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice.
Interruption of inflammatory pathways may provide a novel approach to the therapy of atherosclerosis. Recently, we and others have implicated the immune mediator dyad CD40/CD40L (CD40 ligand), which is expressed on endothelial and smooth muscle cells, macrophages, and T lymphocytes within human atherosclerotic lesions, in aspects of atherogenesis and the acute coronary syndromes, including regulation of matrix metalloproteinases, procoagulant activity, cytokines, etc. In vivo, interruption of CD40 signaling reduced the initiation and early phases of atheroma formation in hypercholesterolemic mice. However, whether interruption of CD40 signaling can retard the progression or even regress established lesions remains unknown. We report here that anti-CD40L antibody treatment of randomly assigned low-density lipoprotein receptor-deficient mice during the second half of a 26-week regimen of high-cholesterol diet did not regress, but did significantly reduce further evolution of established atherosclerotic lesions within the aortic arch and particularly the thoracic and abdominal aorta, as compared with control treatment (application of rat-IgG or saline; 13 weeks, continued high-cholesterol diet). In addition to limiting lesion progression, anti-CD40L treatment changed the composition of atheroma in manners thought to favor plaque stability, e.g., reduced relative content of macrophages and lipid, as well as increased relative content of smooth muscle cells and collagen. These data implicate CD40/CD40L as crucial mediators not only in the initial events of atherogenesis but also during the evolution of established atheroma. This study lends further support to the importance of this specific inflammatory signaling pathway in atherosclerosis and its complications.
Schönbeck
U
U
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, LMRC 309, Boston, MA 02115, USA.
Sukhova
G K
GK
Shimizu
K
K
Mach
F
F
Libby
P
P
D000818:Animals; D000906:Antibodies / Q000008:administration & dosage / Q000276:immunology; D001161:Arteriosclerosis / Q000276:immunology* / Q000503:physiopathology; D019013:CD40 Antigens / Q000276:immunology*; D023201:CD40 Ligand; D004036:Diet, Atherogenic; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000503:physiopathology; D008562:Membrane Glycoproteins / Q000276:immunology*; D051379:Mice; D011973:Receptors, LDL / Q000172:deficiency / Q000276:immunology
D000906:Antibodies; D019013:CD40 Antigens; D008562:Membrane Glycoproteins; D011973:Receptors, LDL; D023201:CD40 Ligand